Table 1.

The current clinical trials for monoclonal antibody treatments available in targeting IL-17.

Drug name	Clinical trial	Details
Secukinumab	FIXTURE trial: full year investigative examination of secukinumab versus eTanercept using 2 dosing regimens to determine efficacy in psoriasis.	Phase III trial using 150 mg and 300 mg of secukinumab ClinicalTrials.gov identifier: NCT01358578
Ixekizumab	UNCOVER-2 trial: a multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of LY2439821 (ixekizumab) to etanercept and placebo in patients With moderate to severe plaque psoriasis.	Phase III trial using 80 mg of ixekizumab ClinicalTrials.gov identifier: NCT01597245
Brodalumab	AMAGINE-2: study to evaluate the efficacy and safety of induction and maintenance regimens of brodalumab compared with placebo and ustekinumab in subjects with moderate to severe plaque psoriasis	Phase III trial using 210 mg and 140 mg of brodalumab ClinicalTrials.gov identifier: NCT01708603